180 degree capital corp (turn) - water absorbent materials

by:Demi     2019-08-22
180 degree capital corp (turn)  -  water absorbent materials
Washington, D. C. Securities and Exchange CommissionC. 20549Form 10-
Quarterly reports submitted under section 13, 15 (d)
Pursuant to the provisions of Section 13, 15, the Securities Trading Act for the quarterly period of section 1934th, 2016 "Transition Report (d)
In the Securities Trading Act of 1934, the transition period from the ___ commision to the Commision commission File Number: 0-
11576 Harris Group Co. , Ltd. (
The exact name of the registrant specified in the articles of association)New York13-3119827(
Of a state or another jurisdiction (I. R. S.
Employer identity number)
Company or organization)
1450 Broadway, New York, New York 10018 (
Main executive office address)(Zip Code)(212)582-0900(
Registrant phone number, including area code)
Indicate by check mark whether the registrant is :(1)
All reports requested by Article 13 or 15 have been submitted (d)
Securities Trading Act of 1934 within the first 12 months (
Or a short period of time required for the registrant to submit such reports), and (2)
This filing requirement has been bound for the last 90 days.
Whether or not the person checking the mark by YesxNo "Indicate also submitted in electronic form and posted on its company website (if any), each interactive data file is required to be submitted and is subject to article 405th S-
12 months before T (
Or in such a short time that the registrant is required to submit and publish these documents).
Indicate by check mark whether the registrant is a large accelerated declarant, a non-accelerated declarant
A smaller reporting company.
See the definition of "large accelerated file manager", "accelerated file manager" and "small Reporting Company" in rule 12b
2 of the Trading Act. (Check one)
: Large accelerated file-accelerated file
Smaller reporting companies (
Do not check if there are smaller reporting companies)
Indicate whether the registrant is a shell company by check mark (
Defined in Rule 12b-
2 parts of the transaction law).
Refers to the number of outstanding shares of the issuer's common shares by the latest practicable date.
Outstanding shares of common stock in August 8, 2016 were $0.
30,880,829 shares per share sharris & Harris Group, Inc. Form 10-
Q: PageNumberPART I, June 30, 2016.
Financial information item 1.
Consolidated financial statements comprehensive assets and liabilities statements comprehensive operating statements Comprehensive loss statements comprehensive cash flow statement comprehensive asset change statements comprehensive investment statements comprehensive financial statements notes Financial advanced statements 2.
Management Discussion and Analysis of financial status and results of operational statements
Looking forward to the future looking forward to the results of the current business environment investment assessment operating financial situation cash flow liquidity and capital resources loan contract obligations accounting policy recent developments-portfolio company 3.
Quantitative and qualitative disclosure of market risks
Part II controls and procedures.
Other information items 1.
Legal action 1A.
Risk factor 2.
Unregistered sales of equity securities and sales of unregistered equity securities.
Default of senior securities 4.
5. safety of the mine.
Other information items 6.
Table 12-Table 1214i-vPART I.
Financial information item 1.
The consolidated financial statements, in the management's view, reflect all adjustments necessary to fairly state our financial position, including valuation adjustments and normal recurring accrual items, business results and cash flows during these periods.
Harris Group Limited® (
"Company", "we" and "we ")
Is an internal management, non-
Choose a diversified management investment company that operates a business development company ("BDC")
According to the Investment Corporation Act of 1940 (the "1940 Act").
Generally, certain information and disclosure of consolidated financial statements are incorporated in accordance with generally accepted accounting principles in the United States ("GAAP")
Has been condensed or omitted as permitted by S-regulations
X and Regulation S-K.
As such, they do not include all the information and disclosures required to fairly state our financial position, results of operations and cash flows in compliance with GAAP.
The results of action during any transition period do not necessarily indicate the results for the whole year.
The accompanying consolidated financial statements shall be read in conjunction with our audited consolidated financial statements and their notes contained in our Annual Report on Form 10
The year ending December 31, 2015.
1 Harris Group Co. , Ltd.
Consolidated statement of assets and liabilities (Unaudited)
June 30, 2016 December 31, 2015 assets investment value investment combination Securities: Non-associated private holding the company (
Cost: $15,732,223 and $18,857,235 respectively)
$6,621,231 $5,376,472 unrelated rights for milestone payment (
Adjusted cost base: $781,863 and $781,863, respectively)
2,993. 8573,362,051 non-related public securities (
Cost: $1,623,029 and $1,623,029 respectively)
552,215957, 544Non-
Holding affiliated private companies (
Cost: $50,377,689 and $49,262,921 respectively)
48,536, 76441,909, 262Non-
Holding listed companies (
Cost: $23,165,788 and $23,165,788 respectively)
9,688, 04818,371,105 holding affiliated private companies (
Cost: $23,679,289 and $23,205,336 respectively)
Private companies with 6,294 and 4277,010,534 equity (
Adjusted cost base: $334,216 and $165,936, respectively)
334,216165, total 936, investment in private portfolio companies, rights to value payments and public securities (
Cost: $115,694,097 and $117,062,108 respectively)
75,020, 75877,152, 904Cash11, 84, 76717, 922,630 funds for value investment sales custody (Note 3)
116,78 1374, accounts receivable of portfolio companies 565, investment sales Accounts receivable 47713,032 (Note 3)
383,5810 receivable99 interest, 81510,333 phone charges expenses358, 135563,699 other assets398 052424,123 Total assets $88,428,366 $96,461,286 debt and net ASSETSTerm loan credit line (Note 5)
Liabilities for the post-retirement plan of $5,000,000 (Note 8)
1,222,360 1,202,148 Accounts payable and accumulated liabiliities671 8281,268,355 Deferred 2017249, 896279,112 commitment and emergencies with total liabilities of $7,144,084 $7,749,615 (Note 11)
Net assets of $81,284,282, net assets of $88,711 include: Preferred shares, $0.
2,000,000 shares authorized at face value 10;
No $0 Common stock, $0 common stock.
01 face value, 45,000,000 shares authorized at 6/30/16 and 12/31/15;
33,218,651 and 33,183,576 are issued at 6/30/16 and 12/31/15, with 186331,836 and additional paid-in capital, respectively (Note 9)
The cumulative net operating and realized losses are 215,674 and 385215,762,973 respectively (89,848,153)(83,377,629)
Accumulated depreciation of investment (40,673,339)(39,909,204)
Accumulated other comprehensive income (Note 8)
220 inventory, cost (
2,337,822 shares, 6/30/16 and 12/31/15)(Note 12)(4,605,525)(4,605,525)
Net assets of $81,284,282, $88,711,671 per share, more than 30 shares, 880,82930 shares, 845 shares, 754 shares. 63$2.
The Unaudited Notes attached are an integral part of these consolidated financial statements.
Harris & Harris Group Limited
Comprehensive Business Report (Unaudited)
Investment income of three months EndedSix EndedJune30, 206june30, 205june30, 206june30, 2015: interest: no company $3,692 $9,533 $6,310 $ Month, 776Non-
96 holding affiliates, 80620,896152, 95 872254,322 holding affiliates, 71847,207186, 14291,633 cash and the United StatesS.
Treasury securities and other expenses for management assistance to portfolio companies 748 (Note 14)
222,97 66, 500. 0,85313, 500Yield-
Debt securities enhancement fee 39, 93319,74 144, 55846,048 Total investment income 084431,027, 042288, 195762, expenses: wages, benefits and stocks-
Basic compensation (Note 9)
617,599977, 6891,221, 5072,056,178 administrative and operational S110, 12018,860252, 412236,094 professional fees349, 74 3314,785648 565887,019 for rent (Note 3)
Debts such as 57, 22167, Medicare 464 Insurance expense67, FedEx, 113141,335 Directs' fees and expenses74, 15168, 901144 760188,525 interest expenses208, 025208, 0uz16 051351,746 custody fees12, FedEx, 69031,616 Depreciation11, 77724,702 total costs 1, 50, 8, 34 81, 87, 3, 50 22, 97, 20174, 052, 679Net operating losses (1,048,306)(1,585,307)(2,210,232)(3,621,652)
Net income achieved (loss)Achieved gain (loss)
Source of investment: non-affiliated companies 5313,289,351 (2,925,462)3,299,836Non-
0 holding related companies (98,644)(1,244,955)(392,430)
Listed companies that have achieved a profit of 4111541,411 (loss)
From investeents233, 5463,232,118 (4,170,402)
2,948,817 Income tax (benefit)expense (Note 10)(1,339)
1,6004, 4911,705 Net gain (loss)
From investeents234, 8853,230,518 (4,174,893)2,947,112Net (increase)
Depreciation reduction in investment: 477,991 of unaffiliated companies (3,782,012)4,369,770(4,405,846)
Holding related companies (176,611)199,923(1,190,061)
357,040 no related rights for milestone payment13,597)(368,194)(12,681)Non-
Holding affiliates 2, 402,78 53, 434,3005, 512,736 (146,818)
Non-public transactions
Holding related companies (3,673,752)(2,353,228)(8,683,057)(601,804)
Listed companies that do not enter the stream (392,208)(601,763)(405,329)
222. net depreciation increase of unrealized investment 951Net (327,707)(3,116,377)(764,135)(4,587,158)
Implemented and not implemented (loss)
Income from investment (92,822)114,141(4,939,028)(1,640,046)
Loss share of equity investment (43,917)(58,330)(85,399)(189,836)
Net decrease in net assets generated by operations: Total $ (1,185,045)$(1,529,496)$(7,234,659)$(5,451,534)
Average $ per share of basic and diluted outstanding shares (0. 04)$(0. 05)$(0. 24)$(0. 17)
Average issued shares
The Unaudited Notes accompanying the basic and diluted 30, 850,98 231, 285,89430, 848,18. 31, 283, 382 are those Consolidated Financial Statements
Harris & Harris Group Limited
Consolidated statement of comprehensive losses (Unaudited)
Three months 30 days, 2016 three months 30 days, 2015 six months 30 days1,185,045)$(1,529,496)$(7,234,659)$(5,451,534)
Other comprehensive losses: Amortization of previous services (benefit)(52,246)(52,246)(104,492)(104,492)
Other comprehensive losses (52,246)(52,246)(104,492)(104,492)
Comprehensive loss of $ (1,237,291)$(1,581,742)$(7,339,151)$(5,556,026)
The Unaudited Notes attached are an integral part of these consolidated financial statements.
Harris & Harris Group Limited
Consolidated Statement of Cash Flow (Unaudited)
Six months EndedJune 30,201 6Six month EndedJune 30, 2015 cash flow for operating activities: Net assets decrease due to business $ (7,234,659)$(5,451,534)
Adjustment to adjust the Net cash used in business activities: Net realized losses and changes in unrealized depreciation of investment 4, 934,5371, depreciation of fixed assets 638,341, amortization of pre-assets and increase in interest on notes (230,834)(279,990)
Loss share of equity investment 85, 399189, 836Stock-
Basic compensation (benefit)expense(65,923)
431,981 Amortization of pre-service (benefit)(104,492)(104,492)
Operating commitment funds for equity investment (253,680)(262,215)
Purchase of related Portfolio Companies (3,450,302)(4,275,915)
Purchase of non-affiliated portfolio companies (698,300)(509,824)
Payment s0186 received by debt investment, repayment of 109 of the bridge notes of the subsidiary portfolio company, and sale of 95039,757,557,846 of The Bridge Notes repayment income of the controlled affiliated portfolio company of the subsidiary portfolio company 750, non-related company income of open transactions is 0000 0100, and asset liability changes are 491: portfolio company receivables (196,445)
143,377 accounts receivable for investment and sales (383,581)
Interest receivable (89,482)(10,344)
Other assets 564200,089,289 (prepaid)138,848)
Post-retirement planned liabilities 20, 21226,347 payable and accrued liabilities (596,527)(167,075)Deferred rent(29,216)(25,712)
Net cash used in operating activities (6,058,548)(2,711,775)
Cash flow from investment activities: Purchase of fixed assets 0 (6,806)
Net cash for investment activities 0 (6,806)
Cash flow of financing activities: the proceeds withdrawn from the loan facility for 05 years, 000,000 of the amount of withholding related to the Net Settlement of restricted stocks (22,315)(47,644)Net cash (used in)
Provided by financing activities (22,315)4,952,356Net (decrease)
$ Cash increase (6,080,863)
$2,233,775 cash start period17 922,63020 the first 748,314 of end when cash $11,841,767 $22,982,089 Cash Flow Statement Supplement disclosure information: Income tax pay 4,491 dollars interest pay 1,705 dollars pay 252,778 dollars. The Unaudited Notes attached are an integral part of these consolidated financial statements.
Harris & Harris Group Limited
Consolidated Statement of Changes in net assets (Unaudited)
Six months EndedJune 30, 2016 year endedecember31, 2015 of the net assets of the action: net loss of $ (2,210,232)$(7,162,510)Net realized (loss)
Income from investment (4,174,893)
4,531. Net increase in unrealized depreciation of investment (764,135)(17,302,729)
Loss share of equity investment (85,399)(312,291)
Net decrease in net assets due to operations (7,234,659)(20,245,830)
Changes in net assets of equity transactions: Purchase of treasury stocks 0 (1,199,994)
Acquisition of a restricted stock award to pay the required employee withholding tax (22,315)(86,914)Stock-
Basic compensation (benefit)expense(65,923)
798. Net assets decreased by 965 due to equity transactions (88,238)(487,943)
Cumulative changes in net assets of other comprehensive losses: other comprehensive losses (104,492)(208,983)
Net decrease in net assets due to accumulated other comprehensive losses (104,492)(208,983)
Net decrease in net assets :(7,427,389)(20,942,756)
Net Assets: $654, $427 at the end of the period 88, 711,671109, 81,284,282 and 88,711. 1 The Unaudited Notes attached are an integral part of these consolidated financial statements
Harris & Harris Group Limited
Schedule of consolidated investment as at June 30, 2016 (Unaudited)
Method Evaluation (1)Major industries (2)
Cost/main value investment in non-affiliated companies (3)-12.
5% of the net assets of the value private equity portfolio (Illiquid)(4)-8.
1% of net assets are at valueBridgelux, Inc. (5)(8)(9)(10)
High energy manufacturing
Power LEDs (LEDs)
Convertible preferred shares with arraysSeries B (
Acquisition 11/29/07)(M)
$1,000,000 1,861,504 $216,402 Series C convertible preferred stock (
Acquisition 7/27/07)(M)
1,352, 1962,130, 699446,626 series D convertible preferred shares (
Acquisition 2/25/08-3/10/10)(M)
1,371, 62299999,999615, 544 series E convertible preferred shares (Get 6/1/11)(M)
672,599440, 334507,418 series E-
1 convertible preferred stock (
Get 3/16/12)(M)
386, 073 399, 579334,596 E Series Convertible preferred stock warrants due to 12/31/17 (
Get 10/21/11)(M)93,969170,823—
8/9/18 maturity of common stock warrants (
Get 1/27/11)(M)148,409171,183—
10/21/18 maturity of common stock warrants (Get 8/9/13)(M)18,81684,846—
5,043,684 2,120,586 fleet Health Alliance Co. , Ltd (5)(8)(9)(11)
Life science development software provides information transfer and consumersUnsecured conversion bridge between health service providers, 0% ,(
Get 4/22/16)(M)
225,000 $225,000225, 000 Mersana treatment, Inc. (5)(8)(9)
Life sciences development of antibody drug binding for cancer treatment
Get 7/27/12)(H)
Series A-3,875, 3953 50, 518. 17, 468-
1 convertible preferred stock (
7/27/12-4/2/14)(H)
683,518. 35, 0811,333,985 Series B-
1 convertible preferred stock (
2/20/15-6/14/16)(H)
365,820339, 887729,5664, 924,7532, 781,019 Mas Laboratory Co. , Ltd. (5)(8)(11)
Life science develops a data analysis platform for precision medical unsecured convertible bridge annotation 5% ,(
Get 5/25/16)(M)
213,075 $212,000213, 075 the Unaudited Notes attached are an integral part of these consolidated financial statements.
Harris & Harris Group Limited
Schedule of consolidated investment as at June 30, 2016 (Unaudited)
Method Evaluation (1)Major industries (2)
Cost/main value investment in non-affiliated companies (3)-12.
5% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(4)-8.
1% of net assets calculated by value (Cont. )Nanosys, Inc. (5)(8)(9)
Energy development of inorganic nanoparticles and quantum dots for LED-
Convertible preferred stock (
Acquisition 4/10/03)(M)
$1,500,000 803,428 $128,337 series D convertible preferred stock (
Get 11/7/05)(M)
3,000, 0031,016, 950433,421 series E-Class convertible preferred shares (
Get 8/13/10)(M)
496, 573433, 688320,8194, 996, 576882, 577 Nano Terra, Inc. (5)(8)
Development of surface chemistry and nanotechnology
Manufacturing Solution warrants due 2/22/21 of common stock (
Get 2/22/11)(I)
69, 1684, Series A 462356 warrants-
3 Preferred Shares due on 11/15/22 (
Get 11/15/12)(I)
57184,584 ferragen company 35,40347, 50884,228104(5)(8)
Convertible bridge note for life science development technology to improve human health and commercial production safety, 5% ,(Get 2/5/15)(M)
214,027 $200,000299, 638 guaranteed convertible Bridge Notes, 5% ,(Get 6/5/15)(M)
$10,537, $390, $ non-affiliated private portfolio (
Fee: $15,732,223)
Milestone Payment rights of $6,621,231 (Illiquid)(6)-3.
7% of ValueAmgen, Inc. net assets(8)(9)
Life Sciences has the right to receive milestone payments from the acquisition of BioVex Group, Inc. (Get 3/4/11)(I)
$548,998 $2,527, and the unaudited notes attached to 629 are an integral part of these consolidated financial statements.
Harris & Harris Group Limited
Schedule of consolidated investment as at June 30, 2016 (Unaudited)
Method Evaluation (1)Major industries (2)
Cost/principle value of milestone payment (Illiquid)(6)-3.
7% of net assets calculated by value (Cont. )Canon, Inc. (8)(9)
Electronic right to obtain milestone payment from acquisition molecular imprint company(
Get 4/18/14)(I)
$232,865 $466,228 detech Co. , Ltd. (8)(9)
Energy rights to receive milestone payments from M & A Nextreme Thermal, Inc. (
Get 2/13)(I)
Total amount of unassociated rights for milestone payment at 0 $00 (cost: $781,863)
Open trading portfolio ($2,993,857)7)-0.
Value echampions economics, Inc. 7% of net assets(5)(9)
Life sciences develop its tumor transplant platform for personalized medicine and drug development
Acquired 3/24/11-3/11/15)(M)
Ordinary shares of warrants of $1,622,629 243,540 $547,721) * 1/28/19 (
Get 1/28/13)(I)
4005,5004, 494 $1,623,029 $552,215 listed securities (
Fee: $1,623,029)
Total investment in non-affiliated companies is $552,215 (
Fee: $18,137,115)
$10,167, 303 the Unaudited Notes attached are an integral part of these consolidated financial statements.
Harris & Harris Group Limited
Schedule of consolidated investment as at June 30, 2016 (Unaudited)
Method Evaluation (1)Major industries (2)
CostShares/principal values are not
Holding related companies (3)-71.
6% of the net assets of the value private equity portfolio (Illiquid)(12)-59.
7% of net assets are at valueABSMaterials, Inc. (5)(8)
Energy development Nano
Structured absorbent materials for water remediation and consumer applications Series A convertible preferred stock (
2/17/10-10/24/11)(I)
$435,000390, 000 $231,918 Series B convertible preferred stock (
Acquired 11/8/13-6/25/14)(I)
1,217, 6441,037, 751978,243, 8% ,(
Get 1/20/16)(M)
103,573 $100,000103, 5731,756,217 1,313,734 AgBiome, LLC (5)(8)(9)
Life sciences provided early
Research and Discovery in the agricultural stage and use crop microbial groups to identify products that reduce risk and increase production
1 convertible preferred stock (
Get 1/30/13)(I)
2,000, 0002,000, 0004,621,038 Series-
2 convertible preferred shares (Acquired 4/9/13-10/15/13)(I)
Convertible preferred shares of Series 3921,005,124 B (Get 8/7/15)(I)
The Unaudited Notes accompanying 500,0061 60, 526571,9973, 021,74 66,198,159 are an integral part of these consolidated financial statements.
Harris & Harris Group Limited
Schedule of consolidated investment as at June 30, 2016 (Unaudited)
Method Evaluation (1)Major industries (2)
CostShares/principal values are not
Holding related companies (3)-71.
6% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(12)-59.
7% of net assets calculated by value (Cont. )D-
Wave Systems(5)(8)(9)(13)
Rapid development of electronic technology
Class B convertible preferred shares (
Acquisition 9/30/08)(H)
1,002 dollar 0741,144,869 dollar 2,536,278 Series 1 Class C class can Conversion preferred stock (
Acquisition 9/30/08)(H)
Class D convertible preferred shares of Class 1, Class 804450, 4501,001,791 series (
Acquisition 9/30/08)(H)
748,473855, Class 1 E Convertible preferred stock of 1311,901,794 series (
Get 11/24/10)(H)
248, 018. 69, 280606,587 series Class 1 class F convertible preferred stock (
Get 11/24/10)(H)
238,323258, Class 1 H Convertible preferred stock of 721582,801 series (
Get 6/27/14)(H)
909,088460, 8661,121,259 Series 2 Class D convertible preferred shares (
Acquisition 9/30/08)(H)
736,020078, 2641,508,446 Series 2 Class E convertible preferred shares (6/1/12-3/22/13)(H)
659,493513, 9001,164,235 series Class 2 class F convertible preferred stock (6/1/12-3/22/13)(H)
63, 63, 1493, 7471,118,578 5/12/19 due to ordinary stock warrants (
Get 5/12/14)(I)
26,35720, 201616,4575, 689,31111 558,226 EchoPixel, Inc. (5)(8)
Developing Life Sciences for virtual reality
D visualization software series seed convertible preferred stock for life sciences and healthcare applications (
Acquired 6/21/13-6/30/14)(I)
1,250, 0004,194, 6301,365,715 series seeds-
2 convertible preferred shares (
Get 1/22/16)(I)
500,0001, 476,668508, 3301,750,000 1,87 4,045 comprehensive treatment company (5)(8)(9)
Developing the life sciences of DNA
Procedural Chemistry for discovering Series B convertible preferred shares for new treatments (Acquisition 6/07)(I)
2,000, 0001,449, 2750 Series B-
1 convertible preferred stock (
Get 4/21/14)(I)
The Unaudited Notes accompanying 679,754492, 5751,289, 6532,679, 7541,289, 653 are integral to these consolidated financial statements.
11 Harris Group Co. , Ltd.
Schedule of consolidated investment as at June 30, 2016 (Unaudited)
Method Evaluation (1)Major industries (2)
CostShares/principal values are not
Holding related companies (3)-71.
6% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(12)-59.
7% of net assets calculated by value (Cont. )HZO, Inc. (5)(8)
Develop new industrial coatings to protect electronic products from liquid common stock (
Get 6/23/14)(H)
Series I convertible preferred stock $666, 667405, 729 $672,553 (
Get 6/23/14)(H)
5,709, 8352,266, 8945,614,379 Series II convertible preferred shares (
Get 6/23/14-8/3/15)(H)
2,500, 006674,6382, 302,053 unsecured convertible bridge note, 10% ,(
Get 6/15/16)(H)
251,096 $250,000307, 8659,127,604 8, 896,850 laser light engine(8)(9)(14)
Solid made of energy
National light source for digital cinema and large cinema
Convertible preferred stock ()Acquisition 5/6/08)(M)
2,000, 0007,499, 0620 Series B convertible preferred shares (
Get 9/17/10)(M)
3,095, 80213,571, 8480, 12% ,(
Acquisition of 10/7/2011)(M)
200,000 $200,0000 guaranteed convertible bridge note, 12% ,(
Get 11/17/11)(M)
95,652 $95,6520 guaranteed convertible bridge, 12% ,(
Acquisition 12/21/2011)(M)
82,609 $82,6090 guaranteed convertible bridge note, 12% ,(
Acquisition. (M)
434,784 $434,78 40 secure convertible bridge note, 12% ,(
Get 7/26/2016)(M)
186,955 $186, 95 50 guaranteed convertible Bridge Notes, 20% ,(
Acquisition 4/29/2015)(M)
Convertible Bridge Notes guaranteed at $166,667, 20% ,(
Get 7/22/2015)(M)
Convertible Bridge Notes guaranteed at $166,667, 10% ,(
Get 10/30/2015)(M)
80,669 $80, 6690 guaranteed convertible Bridge Notes, 10% ,(
Get 2/5/2014)(M)
19,331 $19,3310 guaranteed convertible Bridge Notes, 10% ,(
Get 6/24/2014)(M)
The Unaudited Notes attached to 13,745 13, 74. 06, 542, 8810 are an integral part of these consolidated financial statements.
Harris & Harris Group Limited
Schedule of consolidated investment as at June 30, 2016 (Unaudited)
Method Evaluation (1)Major industries (2)
CostShares/principal values are not
Holding related companies (3)-71.
6% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(12)-59.
7% of net assets calculated by value (Cont. )
Ledo treatment company (5)(8)(9)
New therapies for developing and commercializing self-macro genomes in Life Sciences
A. convertible preferred shares (
12/21/15-4/22/16)(I)
$65, 190658, $190 $670,056 Metabolon, Inc. (5)(8)(9)
Life science develops a biochemical analysis platform for precision medical Series B convertible preferred stock (
Acquisition 6/29/09)(H)
2,500,000 371,7393, 319,486 Series B-
1 convertible preferred stock (
Acquisition 6/29/09)(H)
706,214148, 6961,327,793 Series C convertible preferred stock (
Acquisition 4/30/09)(H)
1,000, 0001,000, 0003,050,329 series D convertible preferred shares (
Get 8/25/11)(H)
1,499, 99935,8822, 569,683 series E-
1 convertible preferred stock (Get 3/2/15)(H)
1,225,000 444,4041, 454,456 series E-
2 convertible preferred shares (Get 3/2/15)(H)
299,999103, 277331,0397, 231,21212, 052,786 ori3n, Inc. (5)(8)(9)
Life Sciences to develop precision medical applications for induced multi-functional stem cell Series 1 convertible preferred stock (2/5/15-8/5/15)(I)
500,0001, 195,3151, 115,811 Series A convertible preferred stock (
Get 11/25/15)(I)
750,000682, 333735,5311, 250,0001, 851,342 Petra pharmaceutical company5)(8)(9)
Life sciences development of small molecule inhibitors for the treatment of cancer and metabolic diseases Series A convertible preferred stock (
Get 12/23/15)(I)
The Unaudited Notes accompanying 1,025, 0501,025, 0501,052, 243 are an integral part of these consolidated financial statements.
Harris & Harris Group Limited
Schedule of consolidated investment as at June 30, 2016 (Unaudited)
Method Evaluation (1)Major industries (2)
CostShares/principal values are not
Holding related companies (3)-71.
6% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(12)-59.
7% of net assets calculated by value (Cont. )
Water absorption company produced(5)(8)(15)
Energy provides integrated process separation solutions for the global oil and gas industry, enabling on-site processing of common water stocks for production and return (
Get 4/30/16)(M)
$7,670,281 50, 243,347 $285,670 ordinary shares due to warrants are closed at the end of the cleaning (
Get 4/30/16)(I)
65, 250450, 0000 senior secured debt, 15% starting at 4/1/16, due at 12/31/19 (Get 4/1/16)(I)
1,910,193 2,533 dollars 7661,494,000 9,645 7241,779,670
Private portfolio of holding subsidiaries (
Fee: $50,377,689)
Open trading portfolio ($48,536,764)16)-11.
9% of net assets in valueAdesto Technology Co. , Ltd (5)(9)(17)
Low power developmentpower, high-
Common inventory of performance memory devices (
Get 10/27/15)(M)
$11,482,417 1,769,868 $5,805,167 Enumeral biomedical Group Co. , Ltd. (5)(9)
Life sciences develop treatment and diagnosis through functional determination of single-cell common stock (
Get 7/31/14)(M)
4,993, 3577,966, 3681,577,341 warrants subscription expires 2/2/2024 (
Get 7/31/14)(I)
57, 567255, 12038,833 warrants for the purchase of ordinary shares due to maturity 7/30/20:9 (
Get 7/31/14)(I)
540,3751, 500,00037, 500 options for the purchase of common stock for $1.
00 expires 7/30/2016 (Get 8/4/14)(I)
080,00005, 591,2991, 653,674 the Unaudited Notes attached are an integral part of these consolidated financial statements.
Harris Group Ltd.
Schedule of consolidated investment as at June 30, 2016 (Unaudited)
Method Evaluation (1)Major industries (2)
Portfolio of open transactions (16)-11.
9% of net assets calculated by value (Cont. )OpGen, Inc. (5)(8)(9)(18)
Life sciences development tools for assembly and analysis of common stock for genomic sequences (Get 5/15)(M)
$5,665,708 1,409,796 $2,142,890 Purchase of common stock is required * 5/8/month (Get 5/15)(M)
Certificate of common stock of 83357,385/25 due at 2/17, 579300 (Get 5/15)(I)
78 53 1,20628, 9326,092,072 2,229,207 Total non
Portfolio of holding related public transactions (
Fee: $23,165,788)
Total non-investment $9,688,048
Holding related companies (
Fee: $73,543,477)
Investment of US $58,224,812 in holding affiliates (3)-7.
8% of the net assets of the value private equity portfolio (Illiquid)(19)-7.
8% of net assets are at valueBlack Silicon Holdings Ltd. (5)(8)(14)(20)
Electronic Technology companies are interested in a company that develops silicon
Series A convertible preferred stock (Get 8/4/15)(I)
$499 $0 Series-
1 convertible preferred stock (Get 8/4/15)(I)
890,0002, 966,6670 Series-
2 convertible preferred shares (Get 8/4/15)(I)
2,445, 0004,207, 5370 Series B-
1 convertible preferred stock (Get 8/4/15)(I)
1,169, 5611,892, 8360 Series C convertible preferred shares (Get 8/4/15)(I)
1,171, 3161,674, 0300, 8% ,(Get 8/4/15)(I)
1,372,775 1,278 dollars 453417,1437 798,652417 143 with of the without audit of note is these with financial report component of the part.
15 Harris Group Co. , Ltd.
Schedule of consolidated investment as at June 30, 2016 (Unaudited)
Method Evaluation (1)Major industries (2)
CostShares/principal values are in the holding company (3)-7.
8% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(19)-7.
8% of net assets calculated by value (Cont. )Interome, Inc. (5)(8)(11)
Develop a platform for precision health and medical inventory (Get 3/1/16)(M)
$101,000,000 $10 guaranteed convertible Bridge Notes, 12% ,(Get 3/1/16)(M)
$300,000 300,000300, 000300,010300, 010NGX Bio, Inc. (5)(8)(21)
Development of seed convertible preferred stock for translation genomics solutions (Get 6/14-1/10/16)(I)
500,002666, 667504,999 Series A convertible preferred stock (
8/20/15-9/30/15)(I)
499,9993 29,989341, 867 unsecured convertible bridge note, 6% (Get 4/6/16)(M)
507,068 $0681,507,069 1,353,934, ProMuc, Inc. (5)(8)
Life sciences development of synthetic sticky protein for nutrition, food and health markets (
Get 12/18/13)(M)
Safety convertible bridge note, 8% ,(
Get 12/18/13)(M)
421,036 $ 8%, 036 secure convertible bridge note ,,(
Get 8/13/14)(M)
115,079 $100,000115, 079 guaranteed convertible Bridge Notes, 8% ,(Get 8/5/15)(M)
80,441 $75, 00080, 441 guaranteed convertible Bridge Notes, 8% ,(
Get 12/7/15)(M)
The Unaudited Notes accompanying $57,495 55,00057, 495674,052674, 052 are an integral part of these consolidated financial statements.
16 Harris Group Co. , Ltd.
Schedule of consolidated investment as at June 30, 2016 (Unaudited)
Method Evaluation (1)Major industries (2)
CostShares/principal values are in the holding company (3)-7.
8% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(19)-7.
8% of net assets calculated by value (Cont. )
Senova Systems(5)(8)
Life Science in the next development
A generation sensor measuring pHSeries B convertible preferred stock (Acquired 9/11-7/18/12)(I)
$1,218, $0 Series B-4621, 350,000
1 convertible preferred stock (Acquired 8/1/13-1/15/14)(I)
1,083, 9602,759, 9020 warrants 4/24/18 of Series B preferred shares expired (
Get 4/24/13)(I)
20, 00025, 0000 Series C convertible preferred shares (
Get 10/24/14-4/1/15)(I)
1,208, 2871,611, 049872,564 warrants 10/15/17 of Series B preferred shares expired (
Get 10/15/12)(I)
131,538164, 4230 safe convertible bridge note, 8% ,(
Get 1/15/16)(I)
261,507 $250,000261, 5073,923,754 1,134,071 SynGlyco, Inc. (5)(8)(14)
Life Sciences developed synthetic carbohydrates for pharmaceutical applications
Get 12/13/11)(I)
2,729, 81757,46 30 series a' convertible preferred stock (
Acquired 12/13/11-6/7/12)(I)
4,855, 6274,855, 6270, 8% ,(
Get 2/26/16)(I)
69,696 $67, 82 352,3397, 655,1452, 339 Tara biological systems(5)(8)
Life sciences develop human tissue models for toxicology and drug discovery applications
Get 8/20/14)(I)
202,000, 000260,000, 8% ,(
Get 8/20/14)(M)
346,440 $300,000519, 660 guaranteed convertible bridge note, 8% ,(
Get 5/18/15)(M)
218,130 $200,000327, 196 guaranteed convertible Bridge Notes, 8% ,(
Get 12/1/15)(M)
1,256,022 1,200 dollars, 0001,256, 0221,820, 6122,362,878 total control private investment combination (
Fee: $23,679,289)
$6,294, 427 The Unaudited Notes attached are an integral part of these consolidated financial statements.
Harris & Harris Group Limited
Schedule of consolidated investment as at June 30, 2016 (Unaudited)
Method Evaluation (1)Major industries (2)
CostShares/principal valuetotal investment holding company (
Fee: $23,679,289)
Total investment in private equity and open trading portfolio is $6,294,427 (
Fee: $115,359,881)
Investment in equity law of $74,686,542 (22)-0.
4% of the net assets of the value private equity portfolio (Illiquid)(22)-0.
Value Accelerator IV 4% of net assets-
New York Corporation (8)(9)(23)
Life Science identification and management of emerging biotechnology companies A common stock (
Get 7/21/14-1/29/16)(E)
AgTech accelerator company $907 $199,726 (8)(9)(11)(23)
Life Science identification and management of common stock of emerging agricultural technology companies (Get 5/4/16)(E)
Investment in 13, 4, 490150 and 000134,490 Total equity laws (cost: $334,216)
Total investment of $334,216 (
Fee: $115,694,097)
The unaudited Note Attached is an integral part of these consolidated financial statements in the amount of $75,020.
Harris & Harris Group Limited
Schedule of consolidated investment as at June 30, 2016 (Unaudited)
Notes to the comprehensive investment schedule (1)
For a description of the "Valuation Procedure", see the "footnote to the consolidated investment schedule" on page 37 ". "(2)
We classify "energy" companies as companies that seek to improve performance, productivity or efficiency and reduce environmental impact, waste, cost, energy consumption or raw materials.
We classify "electronics" companies as companies that solve electronic problems.
Semiconductor, computing and other related industries.
We classify "life science" companies as those that solve life science problems --
Related industries, including precision health and precision medical, biotechnology, agriculture, advanced materials and chemicals, health care, biological processing, water, industrial biotechnology, food, nutrition and energy. (3)
Investments in non-affiliated companies include investments in which we have less than 5% of voting shares in portfolio companies.
Yes.
Holding affiliates include investments in which we own 5% or more of the voting shares of the portfolio company but less than 25%, or where we have one or more seats on the portfolio company's board of directors, but not the company.
Investments in holding affiliates include investments in which we own 25% or more of the voting shares of the portfolio company or otherwise control the company, including controls over the majority of the board seats, or the control of more than 25% of the seats on the board of directors, there is no more board seats than we are controlled by other entities or individuals.
Among the affiliates we control, ProMuc, Inc.
And Interome, Inc.
We have a 100% stake in 2016. (4)
The total cost of federal income tax invested in non-affiliated private holding companies is $15,732,223.
According to the tax costs of these securities, the total unrealized appreciation was $89,826.
The total unrealized depreciation calculated based on the tax costs of these securities is $9,200,818. (5)
All or part of the investment or instruments pledged as collateral under our loan mechanism with Orix corporate Capital Corporation(6)
The total cost of federal income tax for unrelated rights for investment milestone payments is $781,863.
According to the tax costs of these securities, the total unrealized appreciation was $2,211,994.
The total unrealized depreciation calculated based on the tax costs of these securities is $0. (7)
The total cost of federal income tax invested in non-affiliated listed companies is $1,623,029.
The total unrealized appreciation calculated based on the tax costs of these securities is $0.
The total unrealized depreciation calculated based on the tax costs of these securities is $1,070,814. (8)
We are subject to legal restrictions on the sale of our investments (s)
In this company(9)
Express non
Investment Generating income
Investments that have not paid dividends or interest for the past 12 months are considered non-
Generate income. (10)
Bridgelux, Inc. , July 21, 2015.
Signed the final agreement for the acquisition of the investment group led by China Electronics Corporation and Chongqing Linkong Development Investment Corporation.
The transaction ended on August 1, 2016. (11)
Initial investments were made at 2016. (12)
Total cost of non-invested federal income tax
The affiliated private holding company is worth $50,377,689.
According to the tax costs of these securities, the total unrealized appreciation was $14,631,348.
The total unrealized depreciation calculated based on the tax costs of these securities is $16,472,273.
The Unaudited Notes attached are an integral part of these consolidated financial statements.
Harris Group Ltd.
Schedule of consolidated investment as at June 30, 2016 (Unaudited)(13)D-
Wave Systems
Located in Canada, mainly doing business in Canada.
We invested in D-
Corporate waves through parallel universes
A company in Delaware.
Our investment is denominated in Canadian dollars and requires foreign currency translation. See "Note 3.
Summary of major accounting policies. " D-
Wave is not a qualified asset under section 55th (a)
Part of Bill 1940
Under Act 1940, we are not allowed to acquire
Qualified assets, unless at the time of acquisition, qualified assets account for at least 70% of our total assets. (14)
Express non
Operating entities that exist, collect future payments from licenses or other businesses and/or monetize assets for future allocation to investors and debt holders. (15)
Water absorption company produced
Also doing business as ProSep, Inc. (16)
Total cost of non-invested federal income tax
The holding listed company is worth $23,165,788.
The total unrealized appreciation calculated based on the tax costs of these securities is $0.
The total unrealized depreciation calculated based on the tax costs of these securities is $13,477,740. (17)
The company's stake in Adesto Technologies Corporation is locked
We limit our agreement to trade these securities. The lock-
The Up agreement expires on April 25, 2016.
According to article 55th, a total of 200,000 non-eligible assets (a)
Part of Bill 1940
Under Act 1940, we are not allowed to acquire
Qualified assets, unless at the time of acquisition, qualified assets account for at least 70% of our total assets. (18)
Securities of OpGen as of 2016
Locked-
We limit our agreement to trade these securities. The lock-
The Up agreement will expire on August 18, 2016.
According to article 55th, a total of 300,833 shares and 300,833 warrants are not eligible assets (a)
Part of Bill 1940
Under Act 1940, we are not allowed to acquire
Qualified assets, unless at the time of acquisition, qualified assets account for at least 70% of our total assets. (19)
The total cost of federal income tax for investing in controlled affiliates is $23,679,289.
According to the tax costs of these securities, the total unrealized appreciation was $542,266.
The total unrealized depreciation calculated based on the tax costs of these securities is $17,927,128. (20)
August 4, 2015, SiOnyx, Inc.
Restructuring the company structure and becoming a subsidiary of the new company Black Silicon Holding Co. , Ltd.
Our holdings of SiOnyx securities are converted into black silicon Securities.
An undisclosed buyer then acquired SiOnyx.
Black silicon Holdings has a profit interest in undisclosed buyers. (21)
UberSeq, Inc. , August 19, 2015.
, Renamed NGX Bio, Inc. (22)
In private-held equity investments, the total cost of the federal income tax investment is $334,216.
Under the equity law, the investment is made at cost, and after the acquisition date and some other adjustments, the increase or decrease of the net assets of the invested unit, plus or minus the company's equity. (23)See "Note 11.
Promises and surprises.
"The Unaudited Notes attached are an integral part of these consolidated financial statements.
Harris & Harris Group Limited
Valuation method of consolidated investment schedule as of December 31, 2015 (1)
First Industry (2)
Cost/main value investment in non-affiliated companies (3)–11.
0% of the net assets of the value private equity portfolio (Illiquid)(4)–6.
1% of net assets are at valueBridgelux, Inc. (5)(8)(9)(10)
High energy manufacturing
Power LEDs (LEDs)
Convertible preferred shares with arraysSeries B (
Acquisition 11/29/07)(M)
$1,000,000 1,861,504 $258,939 Series C convertible preferred stock (
Acquisition 7/27/07)(M)
1,352, 1962,130, 699534,737 series D convertible preferred shares (
Acquisition 2/25/08-3/10/10)(M)
1,371, 622999,9997 37, 006 series E convertible preferred shares (Get 6/1/11)(M)
672,599440, 334607,572 series E-
1 convertible preferred stock (
Get 3/16/12)(M)
386, 073 399, 579400,630 E Series Convertible preferred stock warrants due to 12/31/17 (
Get 1/27/11)(M)
93,969170, 8230 6/1/16 due to ordinary stock warrants (Get 6/1/11)(M)
Ordinary shares guaranteed by 1000) * 8/9/decree (Get 8/9/13)(M)
148, 409171, common stock guaranteed by 1830) * 10/21/decree (
Get 10/21/11)(M)
Cambrios Technologies Corporation 84605,116, 3522,538,884 ,(5)(8)(9)(11)
NM line for electronic development
Display enabled electronic materials for industry Series B convertible preferred shares (
Acquisition 11/9/04-2/16/05)(M)
1,294, 0251,294, 0250 Series C convertible preferred shares (
Acquisition 3/21/07)(M)
1,300, 0001,300, 0000 Series D convertible preferred shares (Acquisition 8/7/09)(M)
515,756515, 7560 Series D-
2 convertible preferred shares (
Get 5/31/11)(M)
92, 40092, 4000 Series D-
4 convertible preferred shares (
Get 7/12)(M)
216,168216, 16803,418,349 0The note is an integral part of these consolidated financial statements.
21 Harris Group Co. , Ltd.
Valuation method of consolidated investment schedule as of December 31, 2015 (1)
First Industry (2)
Cost/main value investment in non-affiliated companies (3)–11.
0% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(4)–6.
1% of net assets calculated by value (Cont. )Amazing leap company(8)(9)(12)
Electronic Technology for developing new human-computer interaction interfaces and software B. convertible preferred stock (Get 5/1/15)(I )
$338,60429 291 $348,994 Mersana Is treatment Inc. (5)(8)(9)
Life sciences development of antibody drug binding for cancer treatment
1 convertible preferred stock (
7/27/12-4/2/14)(H)
683,518. 35, 081613,892 Series B-
1 convertible preferred stock (
Get 2/20/15)(H)
104,52 197,111104, 407 ordinary shares (
Get 7/27/12)(H)
3,875,395 50,539309, 9634,663,454 1,028,262 Nano Systems(5)(8)(9)
Energy development of inorganic nanoparticles and quantum dots for LED-
Convertible preferred stock (
Acquisition 4/10/03)(M)
1,500, 000803,42828, 853 series D convertible preferred shares (
Get 11/7/05)(M)
3,000, 0031,016, 950597,334 series E-Class convertible preferred shares (
Get 8/13/10)(M)
496, 573433, 688452,6274, 996, 5761, 178,814 Nano Terra, Inc. (5)(8)
Development of surface chemistry and nanotechnology
Manufacturing Solution warrants due 2/22/21 of common stock (
Get 2/22/11)(I )
69, 1684, Series A 462211 warrants-
3 Preferred Shares due on 11/15/22 (
Get 11/15/12)(I )
Notes accompanying 35, 40347, 50861,978104, 57162,189 are an integral part of these consolidated financial statements.
Harris Group Ltd.
Valuation method of consolidated investment schedule as of December 31, 2015 (1)
First Industry (2)
Cost/main value investment in non-affiliated companies (3)–11.
0% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(4)–6.
1% of net assets calculated by value (Cont. )Phylagen, Inc. (5)(8)(13)
Convertible bridge note for life science development technology to improve human health and commercial production safety, 5% ,(Get 2/5/15)(M)
209,041 dollar 200,000 dollar 209,041 dollar 5% dollar ,(Get 6/5/15)(M)
10,288 329 dollars of no associated private investment combination (
Fee: $18,857,235)
Milestone Payment rights of $5,376,472 (Illiquid)(6)–3.
8% of ValueAmgen, Inc. net assets(8)(9)
Life Sciences has the right to receive milestone payments from the acquisition of BioVex Group, Inc. (Get 3/4/11)(I )
$548,998 $2,900,232 detech Co. , Ltd. (8)(9)
Energy rights to receive milestone payments from M & A Nextreme Thermal, Inc. (
Get 2/13)(I )0$00Canon, Inc. (8)(9)
Electronic right to obtain milestone payment from acquisition molecular imprint company(
Get 4/18/14)(I )
232,865 819 dollars milestone payment of no associated rights total (cost: $781,863)
$3,362, 51. the attached notes are an integral part of these consolidated financial statements.
23 Harris Group Co. , Ltd.
Valuation method of consolidated investment schedule as of December 31, 2015 (1)
First Industry (2)
Portfolio of open transactions (7)–1.
Value echampions economics, Inc. 1% of net assets(5)(9)
Life science for developing tumor transplant™Common stock of personalized pharmaceutical and drug development platform (
Acquired 3/24/11-3/11/15)(M)
Ordinary shares of warrants of $1,622,629 243,540 $944,819) * 1/28/19 (
Get 1/28/13)(I )
4005,50012, 7251,623,029 957,544 total portfolio of non-related public transactions (
Fee: $1,623,029)
Total investment in non-affiliated companies is $957,544 (
Fee: $21,262,127)
$9,696,067 non-investment
Holding related companies (3)–67.
9% of the net assets of the value private equity portfolio (Illiquid)(14)–47.
2% of net assets are at valueABSMaterials, Inc. (5)(8)(9)
Energy development Nano
Structured absorbent materials for water remediation and consumer applications Series A convertible preferred stock (
2/17/10-10/24/11)(I )
$435,000390, 000 $160,303 Series B convertible preferred stock (
Acquired 11/8/13-6/25/14)(I )
1,217, 6441,037, 751823,3191, 652,644983, 622 AgBiome, LLC (5)(8)(9)
Life sciences provided early
Research and Discovery in the agricultural stage and use crop microbial groups to identify products that reduce risk and increase production
1 convertible preferred stock (
Get 1/30/13)(I )
2,000, 0002,000, 0004,022,722 Series-
2 convertible preferred shares (Acquired 4/9/13-10/15/13)(I )
Convertible preferred shares of Series 392891,588 B (Get 8/7/15)(I )
Notes accompanying 500,0061 60, 526575,97 93,021 and 74 65,490,289 are integral to these consolidated financial statements.
Harris Group Limited
Valuation method of consolidated investment schedule as of December 31, 2015 (1)
First Industry (2)
CostShares/principal values are not
Holding related companies (3)–67.
9% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(14)–47.
2% of net assets calculated by value (Cont. )D-
Wave Systems(8)(9)(15)
Rapid development of electronic technology
Class B convertible preferred shares (
Acquisition 9/30/08)(H)
1,002 dollar 0741,144,869 dollar 1,485,943 Series 1 Class C class can Conversion preferred stock (
Acquisition 9/30/08)(H)
Class D convertible preferred shares of Class 1, Class 804450, 450588,844 series (
Acquisition 9/30/08)(H)
748,473855, Class 1 E Convertible preferred stock of 1311,117,858 series (
Get 11/24/10)(H)
248, 018. 69, 280368,385 series Class 1 class F convertible preferred stock (
Get 11/24/10)(H)
238,323258, Class 1 H Convertible preferred stock of 721353,940 series (
Get 6/27/14)(H)
909,088460, 866732,972 Series 2 Class D convertible preferred shares (
Acquisition 9/30/08)(H)
736,020078, 264886,651 Series 2 Class E convertible preferred shares (6/1/12-3/22/13)(H)
659,493513, 900711,876 series Class 2 class F convertible preferred stock (6/1/12-3/22/13)(H)
63, 63, 1493, 747683,959 5/12/19 due to ordinary stock warrants (
Get 5/12/14)(I )
4157105,689,311 6, 93, 13 8 EchoPixel, Inc. (5)(8)
Developing Life Sciences for virtual reality
D visualization software series seed convertible preferred stock for life sciences and healthcare applications (
Acquired 6/21/13-6/30/14)(I )
1,250, 0004,194, 6301,327,092, 8% ,(
Get 11/25/15)(M)
The notes accompanying 113,425 $112,500113, 4251,363,425 1,5, 517 are an integral part of these consolidated financial statements.
Harris Group Ltd.
Valuation method of consolidated investment schedule as of December 31, 2015 (1)
First Industry (2)
CostShares/principal values are not
Holding related companies (3)–67.
9% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(14)–47.
2% of net assets calculated by value (Cont. )
Ensemble therapy company (5)(8)(9)
Developing the life sciences of DNA
Program chemistry™Series B convertible preferred shares for the discovery of new categories of treatment (Acquisition 6/07)(I )
2,000 dollar 0001,449,275 dollar 662,607 series
1 convertible preferred stock (
Get 4/21/14)(I )
679,754492, 5751,448,295 2,679, 7542,110,902 HZO, Inc. (5)(8)(9)
Develop new industrial coatings to protect electronic products from liquid common stock (
Get 6/23/14)(I )
66, 667405, 729329,802 series I convertible preferred shares (
Get 6/23/14)(I )
5,709, 8352,266, 8944,281,820 Series II convertible preferred shares (
Get 6/23/14-8/3/15)(I )
Notes accompanying 2,500, 006674,6382, 515,1648, 87, 5087, 126 and 786 are integral to these consolidated financial statements.
Harris & Harris Group Limited
Valuation method of consolidated investment schedule as of December 31, 2015 (1)
First Industry (2)
CostShares/principal values are not
Holding related companies (3)–67.
9% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(14)–47.
2% of net assets calculated by value (Cont. )
Laser Engine Co. , Ltd. (8)(9)
Solid made of energy
National light source for digital cinema and large cinema
Convertible preferred stock ()Acquisition 5/6/08)(M)
Series B convertible preferred shares are $2,000 and $0007,499,062 (
Get 9/17/10)(M)
3,095, 80213,571, 8480, 12% ,(
Get 10/7/11)(M)
200,000 $200,0000 guaranteed convertible bridge note, 12% ,(
Get 11/17/11)(M)
95,652 $95,6520 guaranteed convertible bridge, 12% ,(
Get 12/21/11)(M)
82,609 $82,6090 guaranteed convertible bridge note, 12% ,(Get 3/5/12)(M)
434,784 $434,78 40 secure convertible bridge note, 12% ,(
Get 7/26/12)(M)
186,955 $186, 95 50 guaranteed convertible Bridge Notes, 20% ,(
Get 4/29/13)(M)
Convertible Bridge Notes guaranteed at $166,667, 20% ,(
Get 7/22/13)(M)
Convertible Bridge Notes guaranteed at $166,667, 10% ,(
Get 10/30/13)(M)
80,669 $80, 6690 guaranteed convertible Bridge Notes, 10% ,(Get 2/5/14)(M)
19,331 $19,3310 guaranteed convertible Bridge Notes, 10% ,(
Get 6/24/14)(M)
Lodo treatment company $13,745 (5)(8)(9)(13)
New therapies for developing and commercializing self-macro genomes in Life Sciences
A. convertible preferred shares (
Get 12/21/15)(I )
107,900107, 900107,281 The note is an integral part of these consolidated financial statements.
Harris Group Limited
Valuation method of consolidated investment schedule as of December 31, 2015 (1)
First Industry (2)
CostShares/principal values are not
Holding related companies (3)–67.
9% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(14)–47.
2% of net assets calculated by value (Cont. )Metabolon, Inc. (5)(8)(9)
Life science develops a biochemical analysis platform for precision medical Series B convertible preferred stock (
Acquisition 6/29/09)(M)
2,500 dollar 000371,739 dollar 3,699,120 series
1 convertible preferred stock (
Acquisition 6/29/09)(M)
706,214148, 6961,479,647 Series C convertible preferred stock (
Acquisition 4/30/09)(M)
1,000, 0001,000, 0003,388,907 series D convertible preferred shares (
Get 8/25/11)(M)
1,499, 99935,8822, 887,617 series E-
1 convertible preferred stock (Get 3/2/15)(M)
1,225,000 444,4041, 776,987 series E-
2 convertible preferred shares (Get 3/2/15)(M)
299,999103, 277389,5667, 231,21213, 621,844 ori3n, Inc. (5)(8)(9)(13)
Life Sciences to develop precision medical applications for induced multi-functional stem cell Series 1 convertible preferred stock (2/5/15-8/5/15)(I )
500,0001, 195,315826, 563 Series A convertible preferred stock (
Get 11/25/15)(I )
750,000682, 333750,3381, 250,0001, 576,901 Petra pharmaceutical company5)(8)(9)(13)
Life sciences development of small molecule inhibitors for the treatment of cancer and metabolic diseases Series A convertible preferred stock (
Get 12/23/15)(I )
The notes attached to 1,025, 0501,025, 0501,019, 755 are an integral part of these consolidated financial statements.
28 Harris Group Co. , Ltd.
Valuation method of consolidated investment schedule as of December 31, 2015 (1)
First Industry (2)
CostShares/principal values are not
Holding related companies (3)–67.
9% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(14)–47.
2% of net assets calculated by value (Cont. )
Water absorption company produced(5)(8)(16)
Energy provides integrated process separation solutions for the global oil and gas industry, enabling on-site processing of water Series A convertible preferred stock for production and return (
Get 6/21/11)(M)
$1,000,000 1,000,000 $77,549 Series B convertible preferred shares (
Acquired 6/20/13-3/31/14)(M)
1,496, 8655,987, 460214,302 Series B-
2 convertible preferred shares (
Get 5/12/14)(M)
1,015, 4274,322, 709154,718 Series B-
3 convertible preferred shares (
Get 11/14/13)(M)
Convertible preferred shares of Series 109 C (
Get 5/26/14)(M)
1,000, 2682,667, 38075,581 series D convertible preferred shares (
Get 2/17/15)(M)
98, 6, 06 62, 629,510:3, 330 sub-secured debt, 12%, 6/30/16 due (
Get 10/7/14)(M)
990,634 $1,000,000 560,538 sub-convertible Bridge Notes, 12% ,(
Get 6/3/2015)(M)
267,425 $250,00036, 854 sub-convertible Bridge Notes, 12% ,(
Get 7/15/2015)(M)
263,973 $250,00036, 378 sub-convertible Bridge Notes, 12% ,(
Get 9/28/2015)(M)
257,808 $250,00035, 528 sub-convertible Bridge Notes, 12% ,(
Get 10/30/2015)(M)
255,178 $250,00035, 166 Series B-warrants
2 Preferred Shares due at the time of liquidation (
Get 5/12/14)(I )
The notes accompanying 65,250300, 0001748,577,535 1,500,227 are an integral part of these consolidated financial statements.
Harris & Harris Group Limited
Valuation method of consolidated investment schedule as of December 31, 2015 (1)
First Industry (2)
CostShares/principal values are not
Holding related companies (3)–67.
9% of net assets calculated by value (Cont. )
Private equity portfolio (Illiquid)(14)–47.
2% of net assets calculated by value (Cont. )Ultora, Inc. (5)(8)(17)
Energy development
Convertible preferred stock of carbon nano tubs Series (
Get 12/5/13)(M)
$886,83017, 736 $0 Series B convertible preferred stock (
Get 12/5/13)(M)
236,6032, safety convertible Bridge Notes, 5% ,(Get 5/7/14)(M)
Guaranteed Convertible Bridge, 86,039, 5% ,(
Get 8/20/14)(M)
17,208 $17,2080 guaranteed convertible Bridge Notes, 5% ,(
Get 10/14)(M)
10,750 $10, 7500 safe convertible bridge note, 5% ,(
Get 3/30/15)(M)
7,525 $7, 52501, 244,95 50 total non
Controlling private equity portfolio (
Fee: $49,262,921)
Open trading portfolio ($41,909,262)18)–20.
7% of net assets in valueAdesto Technology Co. , Ltd (5)(8)(9)(19)
Low power developmentpower, high-
Common inventory of performance memory devices (
Get 10/27/15)(M)
$11,482,417 1,769,868 $13,645,682 Enumeral biomedical Group Co. , Ltd. (5)(8)(9)(20)
Life sciences develop treatment and diagnosis through functional determination of single-cell common stock (
Get 7/31/14)(M)
4,993, 3577,966, 3681,831,468 warrants of common stock 7/30/19 due (
Get 7/31/14)(I )
540,3751, 500,00043, 326 ordinary warrants due 2/24 (
Custom message
Chat Online 编辑模式下无法使用
Chat Online inputting...